Dostarlimab - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Dostarlimab

Brand Name:

Jemperli

Strength:

50mg

HCPCS:

NA

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Minor Drug Class:

PD-1

Oral (Y/N):

Yes

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use